Inavolisib
- Generic Name
- Inavolisib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19F2N5O4
- CAS Number
- 2060571-02-8
- Unique Ingredient Identifier
- L4C1UY2NYH
- Background
Inavolisib (GDC-0077) is under investigation in clinical trial NCT03006172 (To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
A Study Evaluating Single-agent Inavolisib and Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT06496568
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇺🇸University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 230
- Registration Number
- NCT05894239
- Locations
- 🇺🇸
Lawrence J. Ellison Institute for Transformative Medicine, Los Angeles, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇨🇳Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, China
A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
- Conditions
- Interventions
- First Posted Date
- 2023-02-01
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 1260
- Registration Number
- NCT05708235
- Locations
- 🇪🇸
Clínica Universidad de Navarra, Madrid, Spain
🇪🇸Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain
🇪🇸Hospital Universitario de Torrejón, Madrid, Spain
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 400
- Registration Number
- NCT05646862
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇧🇷Instituto D'Or de Pesquisa e Ensino, Rio de Janeiro, RJ, Brazil
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
- First Posted Date
- 2022-04-18
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- German Cancer Research Center
- Target Recruit Count
- 240
- Registration Number
- NCT05332561
- Locations
- 🇩🇪
Universitätsklinikum Ulm, Ulm, Bayern, Germany
🇩🇪Universitätsklinikum Carl-Gustav-Carus, Dresden, Sachsen, Germany
🇩🇪National Center for Tumor Diseases, Heidelberg, Baden-Wuerttemberg, Germany
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 170
- Registration Number
- NCT05306041
- Locations
- 🇩🇪
KEM Kliniken Essen-Mitte, Essen, NRW, Germany
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 176
- Registration Number
- NCT04931342
- Locations
- 🇫🇷
CHU Besançon - Hôpital Jean Minjoz, Besançon Cedex, France
🇫🇷Institut Bergonie; Oncologie, Bordeaux, France
🇫🇷Centre Francois Baclesse; Oncologie, Caen, France
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 542
- Registration Number
- NCT04929223
- Locations
- 🇺🇸
cCare, Encinitas, California, United States
🇺🇸Los Angeles Cancer Network, Los Angeles, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Bryan Schneider, MD
- Target Recruit Count
- 197
- Registration Number
- NCT04849364
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Georgetown University, Washington, District of Columbia, United States
🇺🇸Memorial Healthcare System, Hollywood, Florida, United States
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 510
- Registration Number
- NCT04802759
- Locations
- 🇺🇸
Regional Cancer Care Associates LLC (RCCA) - Freehold Location, Freehold, New Jersey, United States
🇺🇸Regional Cancer Care Associates LLC ? Howell Division, Howell, New Jersey, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.